Some of the biggest industries in America aren't glamorous, heavily advertised, or widely discussed—but they quietly generate enormous amounts of revenue every year. Trump blames Iran for helicopter ...

Sustainability is no longer a choice but an urgent business necessity, as organisations face rising environmental challenges, shifting consumer expectations, stricter regulations and increasing ...

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats ...

Four ETFs, each yielding above 6%, each paying monthly. On a $100,000 investment spread across these funds, the income math works out to more than $6,000 a year before taxes. That kind of cash flow is ...

Adventour Singapore has established itself as a leader in organizing Corporate Social Responsibility (CSR) activities, having successfully hosted over 100 companies in their quest to make a positive ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...